Christophe Lacroix,Tomas De Wouters,Gerhard Rogler,Chrlstophe Chassard,Laura Berchtold,Fabienne Kurt,Michael Martin Schari,Marianne Rebecca Spalinger,Markus Relchin,Florian Nils Rosenthal,Marco Meola
申请号：
US16604236
公开号：
US20200276250A1
申请日:
2018.04.12
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to novel compositions comprising specific consortia of living bacteria strains； to the manufacturing of such compositions, particularly by co-cultivation； and to the use of such compositions in pharmaceutical applications, such as the treatment of diseases associated with intestinal microbiota dysbiosis, particularly intestinal infections such as CDI (Clostridium difficile infection) and IBD (Inflammatory bowel diseases). When compared to the traditional FMT therapy () the inventive compositions () are more efficient and safer as demonstrated on an acute colitis model and therefore more appropriate for therapeutic use.
